Stockscreener 앱 받기
2.60
1.96%
0.05
전일 마감가:
$2.55
열려 있는:
$2.6
하루 거래량:
2.25M
Relative Volume:
1.29
시가총액:
$223.82M
수익:
-
순이익/손실:
$-134.24M
주가수익비율:
-1.4689
EPS:
-1.77
순현금흐름:
$-121.34M
1주 성능:
+27.45%
1개월 성능:
+58.05%
6개월 성능:
-49.02%
1년 성능:
-55.86%
1일 변동 폭
$2.585
$2.82
1주일 범위
$2.01
$2.82
52주 변동 폭
$1.285
$7.85
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650)-822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
ANNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.60 | 223.82M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Millennium Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Transcript : Annexon, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
BNP Paribas Financial Markets Makes New $59,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
ProShare Advisors LLC Buys 14,475 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Jane Street Group LLC - Defense World
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference | ANNX Stock News - GuruFocus
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Nuveen Asset Management LLC Acquires 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Ameriprise Financial Inc. - Defense World
Deutsche Bank AG Acquires 28,448 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Northern Trust Corp - Defense World
Annexon reports promising Guillain-Barré treatment results By Investing.com - Investing.com India
Annexon (ANNX) Highlights Promising Results from Tanruprubart Ph - GuruFocus
Annexon reports promising Guillain-Barré treatment results - Investing.com Australia
Annexon Showcases Tanruprubart Data Demonstrating Improved Clini - GuruFocus
Annexon Showcases Tanruprubart Data Demonstrating Improved - GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - The Manila Times
New GBS Drug Shows 3X Better Outcomes Than Standard Care in Clinical Trial | ANNX Stock News - Stock Titan
Annexon Inc (NASDAQ: ANNX) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon (ANNX) Advances with Promising Neurological and Vision T - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Positi - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Position | ANNX Stock News - GuruFocus
Annexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic Diseases - Nasdaq
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
Hsbc Holdings PLC Has $156,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Dimensional Fund Advisors LP Buys 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon Announces Presentations on the Clinical Advancement - GlobeNewswire
Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday - Defense World
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - The Manila Times
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting | ANNX Stock News - GuruFocus
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아넥손 주식 (ANNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
1.21%
1.51%
자본화:
|
볼륨(24시간):